• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Ahmedabad, July 20

Zydus Cadila has received approval from the US Food and Drug Administration (USFDA) to market Meloxicam tablets, 7.5 mg and 15 mg, in the American market.

The company said in a release here that the drug falls in the pain management segment. The branded sales of Meloxicam tablet in the US market in 2005 were pegged at USD $1.26 billion.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Tata Daewoo develops LNG trailer

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line